An update on ICU outcomes in patients after CAR T therapy: A four-year tertiary UK centre experience

1 Introduction Chimeric antigen receptor T- cell (CAR-T) therapy is a novel immune effector treatment for patients with advanced haematological malignancy [1]. In this letter, we present our experience in caring for ICU patients admitted after CAR T therapy. 2 Methods Retrospective analysis of patie...

Full description

Saved in:
Bibliographic Details
Published inJournal of critical care Vol. 80; p. 154511
Main Authors Scourfield, Lily, Pirani, Tasneem, Singh, Neeraj, Saha, Rohit, Kuhnl, Andrea, Sanderson, Robin, Metaxa, Victoria
Format Journal Article
LanguageEnglish
Published United States Elsevier Limited 01.04.2024
Subjects
Clinical outcomes
Cytokines
Hematology
Immunotherapy
Intensive care
Lymphoma
Neurotoxicity
Oncology
Patients
Sepsis
Toxicity
Ventilators
Visualization
United Kingdom > UK
Critical care
Cellular immunotherapy
Haematology
CAR-T
Online AccessGet full text

Cover

More Information
Summary:1 Introduction Chimeric antigen receptor T- cell (CAR-T) therapy is a novel immune effector treatment for patients with advanced haematological malignancy [1]. In this letter, we present our experience in caring for ICU patients admitted after CAR T therapy. 2 Methods Retrospective analysis of patients after CAR-T cell therapy, admitted to a tertiary ICU was conducted between January 2019–December 2022 using digital patient records. The ICU has 89 beds across 6 units, having expanded during the study period from 69.
Bibliography:content type line 23
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
ISSN:0883-9441
1557-8615
1557-8615
DOI:10.1016/j.jcrc.2023.154511